Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT07290010 | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 |
| clinicaltrials |
| NCT02297217 | Chemoradiotherapy for Advanced Esophageal Cancer(PaRCUS) | recruiting | Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04214119 | EsophaCap for the Detection of Early Esophageal Carcinoma | recruiting | — | 2,500 | Johns Hopkins UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07283991 | QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer(BRICES) | not yet recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06532734 | Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype | recruiting | — | 25 | Denver Health and Hospital AuthorityOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07061704 | Oncolytic Virus in Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 40 | Sichuan UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07266493 | Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06430346 | Exercise Prehabilitation for Locoregional Esophageal Cancer | recruiting | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05307835 | Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection | active not recruiting | Phase 1 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06576973 | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04974047 | Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma(RATIONALE-213) | completed | Phase 2 | 70 | BeiGeneINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07155330 | High-flow Nasal Cannula Oxygenation in Sedated Endoscopy for High-risk Obstructive Sleep Apnea Patients | completed | N/A | 80 | Zhejiang UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07196384 | Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW(GLOW) | not yet recruiting | Phase 1 | 15 | University Medical Center GroningenOTHER | 0 | Nov 21, 2025 | clinicaltrials |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT) | active not recruiting | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07236320 | Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC | completed | N/A | 200 | Yongtao HanOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06912074 | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07086469 | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06129487 | Evaluations of Alcohol Warning Labels | completed | N/A | 1,053 | University of ConnecticutOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02372929 | Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer(ESOCA) | completed | — | 100 | AdventHealthOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05563766 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | recruiting | Phase 2 | 78 | VA Office of Research and DevelopmentFED | 1 | Nov 5, 2025 | clinicaltrials |
| NCT01191697 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT04408105 | Survey Study on Barrett's Esophagus Screening(SCREEN-BE) | completed | — | 725 | University of Colorado, DenverOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03819088 | Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer | completed | N/A | 17 | Emory UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03551951 | Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow | recruiting | — | 320 | University of Missouri-ColumbiaOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT07211009 | Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial | not yet recruiting | Phase 3 | 240 | Sichuan UniversityOTHER | 0 | Oct 7, 2025 | clinicaltrials |
| NCT04526886 | Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy | completed | N/A | 52 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05051475 | Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus(RATE) | completed | N/A | 62 | Centre of Postgraduate Medical EducationOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06192212 | PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy | completed | — | 577 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06869213 | A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06869226 | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer | recruiting | Phase 2 | 283 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | recruiting | Phase 1 | 108 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07203690 | Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology | not yet recruiting | — | 7,000 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2025source: clinicaltrials